Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study

BMC Cancer

Martin C Boonstra¹  Floris PR Verbeek¹  Andrew P Mazar³  Hendrica AJM Prevoo¹  Peter JK Kuppen¹  Cornelis JH van de Velde¹  Alexander L Vahrmeijer¹  Cornelis FM Sier² 

[1] Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands

[2] Antibodies for Research Applications BV, Gouda, The Netherlands

[3] Chemistry of Life Processes Institute and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, IL, USA

关键词: Macrophage;    Tumor associated stromal cell;    Survival;    Diagnosis;    Immunohistochemistry;    Urokinase receptor;   

Others  :  858888
DOI  :  10.1186/1471-2407-14-269

 received in 2013-03-20, accepted in 2014-04-03,  发布年份 2014

【 摘 要 】

Background

The receptor for urokinase-type plasminogen activator (uPAR) is associated with cancer development and progression. Within the tumor microenvironment uPAR is expressed by malignant cells as well as tumor-associated stromal cells. However, the contribution of uPAR expression in these stromal cells to malignancy and patient survival in colorectal cancer is still unclear. This study compares the association of uPAR expression in both colorectal tumor-associated stromal cells and neoplastic cells with clinico-pathological characteristics and patient survival using tissue micro arrays (TMA).

Methods

Immunohistochemical staining of uPAR expression was performed on tumor tissue from 262 colorectal cancer patients. Kaplan-Meier, log rank, and uni- and multivariate Cox’s regression analyses were used to calculate associations between uPAR expression and patient survival.

Results

In the colorectal tumor-associated stromal microenvironment, uPAR is expressed in macrophages, (neoangiogenic) endothelial cells and myofibroblasts. uPAR expression in tumor-associated stromal cells and neoplastic cells (and both combined) were negatively associated with overall survival (OS) and Disease Free Survival (DFS). Uni- and multivariate Cox’s regression analysis for combined uPAR expression in tumor-associated stromal and neoplastic cells showed significant and independent negative associations with OS and DFS. Only uPAR expression in tumor-associated stromal cells showed independent significance in the uni- and multivariate analysis for DFS.

Conclusion

This study demonstrates a significant independent negative association between colorectal cancer patient survival and uPAR expression in especially tumor-associated stromal cells.

【 授权许可】

   
2014 Boonstra et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Center MM, Jemal A, Smith RA, Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin 2009, 59:366-378.
• [2]Ogino S, Fuchs CS, Giovannucci E: How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012, 12:621-628.
• [3]Boonstra MC, Verspaget HW, Ganesh S, Kubben FJ, Vahrmeijer AL, van de Velde CJ, Kuppen PJ, Quax PH, Sier CF: Clinical applications of the urokinase receptor (uPAR) for cancer patients. Curr Pharm Des 2011, 17:1890-1910.
• [4]Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, Romer J: Plasminogen activation and cancer. Thromb Haemost 2005, 93:676-681.
• [5]Vassalli JD, Baccino D, Belin D: A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985, 100:86-92.
• [6]Schlechte W, Murano G, Boyd D: Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res 1989, 49:6064-6069.
• [7]Blasi F, Sidenius N: The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010, 584:1923-1930.
• [8]Pyke C, Kristensen P, Ralfkiaer E, Grøndahl-Hansen J, Eriksen J, Blasi F, Danø K: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991, 138:1059-1067.
• [9]Sier CF, Quax PH, Vloedgraven HJ, Verheijen JH, Griffioen G, Ganesh S, Lamers CB, Verspaget HW: Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases. Invasion Metastasis 1993, 13:277-288.
• [10]Allgayer H: Translational research on u-PAR. Eur J Cancer 2010, 46:1241-1251.
• [11]Hildenbrand R, Schaaf A: The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int J Oncol 2009, 34:15-23.
• [12]Illemann M, Bird N, Majeed A, Laerum OD, Lund LR, Danø K, Nielsen BS: Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 2009, 124:1860-1870.
• [13]Blok EJ, Kuppen PJ, Van Leeuwen JE, Sier CF: Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. Clin Med Insights Oncol 2013, 7:41-51.
• [14]Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L, Furie B, Furie BC, Cines DB, Huang M: Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006, 311:656-659.
• [15]Grøndahl-Hansen J, Peters HA, Van Putten WL, Look MP, Pappot H, Rønne E, Danø K, Klijn JG, Brünner N, Foekens JA: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995, 1:1079-1087.
• [16]Kotzsch M, Bernt K, Friedrich K, Luther E, Albrecht S, Gatzweiler A, Magdolen V, Baretton G, Zietz C, Luther T: Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma. Histopathology 2010, 57:461-471.
• [17]Kim SJ, Shiba E, Taguchi T, Watanabe T, Tanji Y, Kimoto Y, Izukura M, Takai SI: Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. Anticancer Res 1997, 17:1373-1378.
• [18]Giannopoulou I, Mylona E, Kapranou A, Mavrommatis J, Markaki S, Zoumbouli C, Keramopoulos A, Nakopoulou L: The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomas. Cancer Lett 2007, 246:262-267.
• [19]Li Y, Parry G, Chen L, Callahan JA, Shaw DE, Meehan EJ, Mazar AP, Huang M: An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope. J Mol Biol 2007, 365:1117-1129.
• [20]Halamkova J, Kiss I, Pavlovsky Z, Jarkovsky J, Tomasek J, Tucek S, Hanakova L, Moulis M, Cech Z, Zavrelova J, Penka M: Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients. Hepatogastroenterology 2011, 58:1918-1925.
• [21]Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Andersen J, Overgaard J: Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol 2008, 47:591-599.
• [22]Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987, 8:138-140.
• [23]Alpizar-Alpizar W, Christensen IJ, Santoni-Rugiu E, Skarstein A, Ovrebo K, Illemann M, Laerum OD: Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma. Int J Cancer 2012, 131:E329-E336.
• [24]Ohtani H, Pyke C, Dano K, Nagura H: Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis. Int J Cancer 1995, 62:691-696.
• [25]Otranto M, Sarrazy V, Bonte F, Hinz B, Gabbiani G, Desmouliere A: The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr 2012, 6:203-219.
• [26]Erreni M, Mantovani A, Allavena P: Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron 2011, 4:141-154.
• [27]De Wever O, Demetter P, Mareel M, Bracke M: Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008, 123:2229-2238.
• [28]Zhang J, Sud S, Mizutani K, Gyetko MR, Pienta KJ: Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 2011, 13:23-30.
• [29]Vong S, Kalluri R: The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. Genes Cancer 2011, 2:1139-1145.
• [30]Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F: The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998, 58:1843-1849.
• [31]Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Danø K, Brünner N: Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999, 91:869-874.
• [32]Lomholt AF, Christensen IJ, Høyer-Hansen G, Nielsen HJ: Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol 2010, 49:805-811.
• [33]Taubert H, Wurl P, Greither T, Kappler M, Bache M, Lautenschlager C, Fussel S, Meye A, Eckert AW, Holzhausen HJ, Magdolen V, Kotzsch M: Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br J Cancer 2010, 102:731-737.
• [34]Kjellman A, Akre O, Gustafsson O, Høyer-Hansen G, Lilja H, Norming U, Piironen T, Tornblom M: Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening. J Intern Med 2011, 269:299-305.
• [35]Almasi CE, Brasso K, Iversen P, Pappot H, Høyer-Hansen G, Danø K, Christensen IJ: Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate 2011, 71:899-907.
• [36]Sier CF, Nicoletti I, Lisa SM, Frandsen T, Aletti G, Ferrari A, Lissoni A, Giavazzi R, Blasi F, Sidenius N: Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thromb Haemost 2004, 91:403-411.
• [37]Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, Kerfoot CA, Mazar AP: An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia 2010, 12:778-788.
• [38]Van Buren G, Gray MJ, Dallas NA, Xia L, Lim SJ, Fan F, Mazar AP, Ellis LM: Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer 2009, 115:3360-3368.
• [39]Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel E: Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res 2011, 17:459-471.